Loading…

Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-10, Vol.22, p.S124
Main Authors:	DiNardo, Courtney D., de Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Löwenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Döhner, Hartmut, Fathi, Amir T., Martin-Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., Hasan, Maroof
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!